Revolution Medicines 2023 annual meeting results: directors elected, auditor ratified, say-on-pay approved

Revolution Medicines, Inc.

Alexis Borisy re-elected to Class III with 41.5M votes for, 48.0M withheld; Mark Goldsmith and Barbara Weber elected with margins >70M.
PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 94.9M for, 6,594 against.
Non-binding advisory vote on named executive officer compensation passed with 88.7M for, 0.8M against, 5.3M broker non-votes.
Only three proposals were voted on; no other items presented at the annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Revolution Medicines, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected and qualified. at the 2023-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

Proposal 1 . The Company’s stockholders elected three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected and qualified. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Alexis Borisy 41,488,497 48,023,150 5,346,837 Mark A. Goldsmith, M.D., Ph.D. 87,159,600 2,352,047 5,346,837 Barbara Weber, M.D. 73,933,569 15,578,078 5,346,837

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Revolution Medicines, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

Proposal 2 . The Company’s stockholders ratified the appointment, by the audit committee of the Company’s board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 94,850,743 6,594 1,147

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Revolution Medicines, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2023-06-08 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

Proposal 3 . The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 88,731,273 773,142 7,232 5,346,837

View on SEC.gov

637 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-164446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.